2025
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.
Levring MB, Diaz-delCastillo M, Gundesen MT, Cédile O, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Kassem M, Abildgaard N, Andersen TL, Lund T. Bone. 2025
Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
Hansen MH, Gulmir R, Cédile O, Dahlmann SK, Veyhe SR, Stougaard M, Juul-Jensen K, Nyvold CG. Eur J Haematol. 2025
Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics.
Vimalathas G, Hansen MH, Cédile O, Thomassen M, Møller MB, Dahlmann SK, Kjeldsen MLG, Hildebrandt MG, Nielsen AL, Naghavi-Behzad M, Edenbrandt L, Nyvold CG, Larsen TS. Blood Adv. 2025
Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non-Hodgkin Large B-Cell Lymphoma: A Comparative Study of Cell-Free DNA and Formalin-Fixed Paraffin-Embedded Tissue.
Vimalathas G, Cédile O, Kjeldsen MLG, Thomassen M, Møller MB, Nyvold CG, Hansen MH, Larsen TS. Int J Lab Hematol. 2025
A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
Veyhe SR, Hansen MH, Cédile O, Møller MB, Nielsen MK, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Nyvold CG. Eur J Haematol. 2025
Multilevel Analysis of MYC and BCL2 Aberrations in Diffuse Large B-Cell Lymphoma: Identifying a High-Risk Patient Subgroup Across Cell-of-Origin Using Targeted Sequencing.
Vimalathas G, Lang CS, Green TM, Møller MB, Nyvold CG, Hansen MH, Larsen TS. Eur J Haematol. 2025
2024
Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia.
Veyhe SR, Cédile O, Dahlmann SK, Krejcik J, Abildgaard N, Høyer T, Møller MB, Thomassen M, Juul-Jensen K, Frederiksen H, Dybkær K, Hansen MH, Nyvold CG. Int J Mol Sci. 2024
SWIGH-SCORE: A translational light-weight approach in computational detection of rearranged immunoglobulin heavy chain to be used in monoclonal lymphoproliferative disorders.
Hansen MH, Maagaard M, Cédile O, Nyvold CG. MethodsX. 2024
2023
The potential of 3rd-generation nanopore sequencing for B-cell clonotyping in lymphoproliferative disorders.
Hansen MH, Cédile O, Abildgaard N, Nyvold CG. EJHaem. 2023
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T. Cancers (Basel). 2023
Toward Cytogenomics: Technical Assessment of Long-Read Nanopore Whole-Genome Sequencing for Detecting Large Chromosomal Alterations in Mantle Cell Lymphoma.
Hansen MH, Cédile O, Kjeldsen MLG, Thomassen M, Preiss B, von Neuhoff N, Abildgaard N, Nyvold CG. J Mol Diagn. 2023
Cell-free DNA for detection of clonal B cells in diffuse large B cell lymphoma by sequencing.
Højlund EL, Cédile O, Larsen TS, Vimalathas G, Møller MB, Hansen MH, Nyvold CG. Int J Lab Hematol. 2023
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.
Diaz-delCastillo M, Gundesen MT, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Abildgaard N, Levin Andersen T, Lund T. J Bone Miner Res. 2023
Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing.
Cédile O, Hansen MH, Dahlmann SK, Kristensen TK, Abildgaard N, Nyvold CG. Exp Hematol. 2023
2022
Comparative evaluation of the heterozygous variant standard deviation as a quality measure for next-generation sequencing.
Høy Hansen M, Steensboe Lang C, Abildgaard N, Nyvold CG. J Biomed Inform. 2022
Methylation microarray-based detection of clinical copy-number aberrations in CLL benchmarked to standard FISH analysis.
Hussmann D, Starnawska A, Kristensen L, Daugaard I, Cédile O, Nguyen VQ, Kjeldsen TE, Hansen CS, Bybjerg-Grauholm J, Kristensen T, Larsen TS, Møller MB, Nyvold CG, Hansen LL, Wojdacz TK. Genomics. 2022
Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.
Elkjær LAL, Cédile O, Hansen MH, Nielsen C, Møller MB, Abildgaard N, Haaber J, Nyvold CG. Leuk Res Rep. 2022
Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia.
Karlsson L, Nyvold CG, Soboli A, Johansson P, Palmqvist L, Tierens A, Hasle H, Lausen B, Jónsson ÓG, Jürgensen GW, Ebbesen LH, Abrahamsson J, Fogelstrand L. Int J Lab Hematol. 2022
Mantle cell lymphoma and the evidence of an immature lymphoid component.
Hansen SV, Nyvold CG, Hansen MH. Leuk Res. 2022
Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments.
Simonsen AT, Meggendorfer M, Hansen MH, Nederby L, Koch S, Hansen M, Rosenberg CA, Kern W, Nyvold CG, Aggerholm A, Haferlach T, Ommen HB. Exp Hematol. 2022
Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
Knudsen AM, Halle B, Cédile O, Burton M, Baun C, Thisgaard H, Anand A, Hubert C, Thomassen M, Michaelsen SR, Olsen BB, Dahlrot RH, Bjerkvig R, Lathia JD, Kristensen BW. Neuro Oncol. 2022
Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
Hasle H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, Bhojwani D, Verboon JM, DiTroia SP, Chao KR, Raaschou-Jensen K, Palle J, Zwaan CM, Nyvold CG, Sankaran VG, Cantor AB. Blood. 2022
IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load.
Hussmann D, Starnawska A, Kristensen L, Daugaard I, Thomsen A, Kjeldsen TE, Hansen CS, Bybjerg-Grauholm J, Johansen KD, Ludvigsen M, Kristensen T, Larsen TS, Møller MB, Nyvold CG, Hansen LL, Wojdacz TK. Haematologica. 2022
2021
Investigation of circulating DNA integrity after blood collection.
Cédile O, Veyhe SR, Hansen MH, Titlestad K, Nyvold CG. Biotechniques. 2021
Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia.
Skou AS, Juul-Dam KL, Hansen M, Lausen B, Stratmann S, Holmfeldt L, Aggerholm A, Nyvold CG, Ommen HB, Hasle H. J Mol Diagn. 2021
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4.
Valentin Hansen S, Høy Hansen M, Cédile O, Møller MB, Haaber J, Abildgaard N, Guldborg Nyvold C. Sci Rep. 2021
Harnessing the Immune System to Fight Multiple Myeloma.
Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Cancers (Basel). 2021
Replicate whole-genome next-generation sequencing data derived from Caucasian donor saliva samples.
Hansen MH, Nyvold CG. Data Brief. 2021
Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma.
Hansen MH, Juul-Jensen K, Cédile O, Kavan S, Møller MB, Haaber J, Nyvold CG. Leuk Res Rep. 2021
Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?
Hansen MH, Cédile O, Larsen TS, Abildgaard N, Nyvold CG. Exp Hematol. 2021
2020
Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Juul-Dam KL, Ommen HB, Nyvold CG, Walter C, Vålerhaugen H, Kairisto V, Abrahamsson J, Alm SJ, Jahnukainen K, Lausen B, Reinhardt D, Zeller B, von Neuhoff N, Fogelstrand L, Hasle H. Br J Haematol. 2020
Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.
Hansen MH, Cédile O, Blum MK, Hansen SV, Ebbesen LH, Bentzen HHN, Thomassen M, Kruse TA, Kavan S, Kjeldsen E, Kristensen TK, Haaber J, Abildgaard N, Nyvold CG. Exp Hematol. 2020
Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.
Abildgaard N, Rojek AM, Møller HE, Palstrøm NB, Nyvold CG, Rasmussen LM, Hansen CT, Beck HC, Marcussen N. Amyloid. 2020
A decade with whole exome sequencing in haematology.
Hansen MC, Haferlach T, Nyvold CG. Br J Haematol. 2020
2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Clin Cancer Res. 2019
Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood.
Løvvik Juul-Dam K, Ifversen M, Guldborg Nyvold C, Hansen M, Hasle H. J Pediatr Hematol Oncol. 2019
Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report.
Iversen KF, Holdgaard PC, Preiss B, Nyvold CG, Plesner T. Haematologica. 2019
Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K, Guldborg Nyvold C, Vålerhaugen H, Zeller B, Lausen B, Hasle H, Beier Ommen H. Pediatr Blood Cancer. 2019
Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma.
Nielsen PI, Hansen SV, Møller MB, Kristensen TK, Cédile O, Hansen MC, Ebbesen LH, Haaber J, Abildgaard N, Nyvold CG. Leuk Res. 2019
2018
Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment.
Daugaard I, Hussmann D, Kristensen L, Kristensen T, Kjeldsen TE, Nyvold CG, Larsen TS, Møller MB, Hansen LL, Wojdacz TK. Epigenomics. 2018
